Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 28, 2024
Context: This filing reports on the progress of the company's share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 69,000 people and operating in around 170 countries.
Key Financial Metrics
This filing focuses on capital allocation via share buybacks rather than operational financial performance (revenue, profit, or cash flow). Key metrics include:
- Share Repurchase Programme Cap: Up to DKK 20 billion over a 12-month period beginning February 6, 2024.
- Specific Sub-Programme (Aug 7 - Nov 4, 2024): Up to DKK 2.4 billion.
- Total Repurchased (Since Feb 6, 2024): 13,597,148 B shares.
- Total Transaction Value (Since Feb 6, 2024): DKK 11,901,762,964.
- Average Share Price (Since Feb 6, 2024): DKK 875.31 per B share.
- Treasury Shares Held: 14,925,779 B shares (0.3% of share capital).
- Total Share Capital: 4,465,000,000 shares (including treasury shares).
Material Changes
The filing details transactions executed between October 21, 2024, and October 25, 2024, under the sub-programme initiated on August 7, 2024:
| Date | Number of B Shares | Avg. Purchase Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| Oct 21, 2024 | 46,000 | 807.65 | 37,151,878 |
| Oct 22, 2024 | 46,000 | 798.87 | 36,748,058 |
| Oct 23, 2024 | 46,500 | 801.76 | 37,281,937 |
| Oct 24, 2024 | 47,000 | 796.42 | 37,431,850 |
| Oct 25, 2024 | 48,000 | 784.32 | 37,647,367 |
| Accumulated (Sub-programme) | 2,530,022 | - | 2,174,056,914 |
As of October 25, 2024, the company has utilized approximately 59.5% of the total DKK 20 billion programme authorization.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 20 billion limit during the 12-month period starting February 6, 2024. The specific sub-programme referenced in this filing is scheduled to conclude on November 4, 2024.
Risks/Contingencies: The filing does not disclose new operational risks or contingencies. It notes that transaction details are published on the company website and that the programme adheres to EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining authorization under the DKK 20 billion programme (approx. DKK 8.1 billion remaining as of Oct 25).
- Confirm the end date of the current sub-programme (November 4, 2024) and whether a new sub-programme will be announced.
- Review the company's website (novonordisk.com) for daily transaction details as referenced in the filing.
- Note that this filing does not contain Q3 or full-year 2024 financial results (revenue, earnings, or cash flow); those are reported in separate filings.